GLP-1 Prior Authorization Denied: Appeal, Correct the Request or Pay Cash?

A denied Wegovy or Zepbound authorization is a reason to read the decision before opening your wallet. The next move depends on what was denied: a benefit your plan excludes, a request missing evidence, or a drug subject to a coverage rule. An appeal addresses a disputed decision. A corrected submission addresses an incomplete record. Cash payment addresses the immediate bill. Start with the stated reason for the denial.

Aetna's pharmacy guidance explicitly identifies an appeal, a clinician-selected alternative and self-payment as possible responses to a denied authorization. It also directs members to their own plan documents for GLP-1 coverage.¹ The framework below helps you prepare that conversation; it cannot determine what your particular policy owes.

Start with the letter, not the pharmacy price

Get the written denial and the current policy or benefit provision cited in it. Record the requested drug and formulation, the denial date, the reference number, the stated reason and the instructions for challenging it. Ask whether the pharmacy message represents a completed coverage decision or a request that the prescribing office has not yet finished.

Keep a copy of everything you send, plus a dated log of calls and submission confirmations. HealthCare.gov recommends retaining the denial, appeal paperwork, supporting clinical documents and notes of conversations with the insurer.² A short record of who has which document can prevent another week of the pharmacy, office and plan referring you to one another.

Use the insurance coverage overview if the difference between a covered drug and a covered use is still unclear. Then choose the branch that matches the letter.

If the benefit is excluded

Ask the plan to identify the exact exclusion and confirm that it applies to this prescription's actual use. “Weight-management medicines are excluded” is a different problem from “this brand is not preferred.” Ask whether a benefit exception or appeal route exists and what it can consider. A letter explaining clinical need should address the decision actually made; it is not a promise that an excluded benefit becomes payable.

For employer coverage, the benefits office can help locate the governing plan documents and identify the administrator. For Medicare, check whether the prescription should be handled by ordinary Part D or the separate Medicare GLP-1 Bridge. Do not assume a Part D rejection automatically establishes Bridge eligibility. Have the clinician document the real condition and treatment purpose, rather than requesting a diagnosis chosen to obtain coverage.

If records are missing or the request used the wrong criteria

Ask the prescribing office for a sentence-by-sentence comparison between the denial and the submitted record. For example: did the plan request a dated starting BMI, and did the office supply only today's measurement? Did the request concern continuing treatment while the reviewer applied an initial-treatment requirement? These are questions to investigate, not assumptions that the insurer made an error.

Have the office identify the actual missing evidence, obtain it and confirm whether the plan wants a corrected submission or a formal appeal. Ask explicitly whether resubmission changes the appeal deadline; do not let an informal retry consume the time available to challenge the decision. Aetna notes that prior authorization can require diagnosis, laboratory results or other medical-record information, and an expired authorization may need a new request.¹

If the plan requires another drug first

Step therapy means the plan requires an alternative before it covers the requested drug. Ask which alternative, what evidence of prior treatment is required and whether the clinician can request an exception. Aetna describes that option as dependent on the member's plan.¹

For ordinary Medicare Part D, a formulary exception can request coverage of a nonformulary Part D drug or waiver of a utilization rule such as step therapy. CMS requires a prescriber's supporting statement explaining why the alternatives would be less effective or have adverse effects, as applicable. That is clinical evidence about this patient, not a generic statement that a popular drug works well.³

Put the right deadline on the calendar

There is no universal GLP-1 appeal clock. HealthCare.gov's internal-appeal guidance describes a 180-day filing period after the denial notice for the private health-plan process it covers, with decisions generally within 30 days for care not yet received or 60 days for care already received. Confirm the process that applies to your coverage in your notice.²

Ordinary Medicare Part D is different: CMS says a redetermination request is due within 65 calendar days of the coverage-determination notice date. For benefit requests, the plan generally has seven calendar days for a standard redetermination or 72 hours for an expedited one; payment appeals have a different 14-day decision period. An unfavorable decision explains how to request independent reconsideration.⁴

For a Part D exception request, the earlier coverage-decision clock is generally 72 hours standard or 24 hours expedited after receipt of the prescriber's supporting statement. Do not confuse that initial decision with the appeal timetable.³ Ask the clinician whether the medical circumstances justify an expedited request; the urgency of a refill needs clinical assessment.

If a private plan maintains its denial, read its external-review instructions. HealthCare.gov explains that eligible external reviews can place certain disputes before an independent reviewer, and that state and federal processes differ.⁵ An internal denial is not always the last step.

Price the cash option while preserving your choices

Request a cash quote for the exact prescribed product, dose and supply. Add the visits, membership, labs and shipping you would actually pay. Record whether a discount ends, requires recurring enrollment or applies only to certain patients. Ask whether a cash purchase could be reimbursed after a successful appeal; treat reimbursement as unknown until the plan confirms the conditions.

Use our six-month cost comparison to organize the arithmetic. Six fills at an illustrative $300 each cost $1,800 before other fees; the example is a budgeting exercise, not an available offer. Decide how many fills you could afford if the appeal remains unsuccessful, rather than basing the purchase on an expected reversal.

A new provider may help with administration, but paying another membership fee does not resolve the denial by itself. If you are considering Ro or Sesame Care, ask who handles the submission, whether appeals are included, and what you owe while a decision is pending. Have the current clinician plan any interruption or change in treatment.

Leave the call with a specific next action

Aim to finish with four things: the reason for denial, the evidence or decision being challenged, the person responsible for the next submission, and its deadline. “Insurance is working on it” is not enough information to budget around.

Source check: October 6, 2026. This article reviews public CMS, HealthCare.gov and Aetna guidance; it does not review your policy or claim a benefits-specialist assessment. The insurer example illustrates a process, not a nationwide promise of coverage. Follow your notice and request case-specific help when the stated rules and your records disagree.